Hope for kids with rare genetic disorder

accreditation
www.mirror.co.uk

Babies born with so-called "bubble boy" disease can often be cured with a stem cell transplant, regardless of the donor - but early treatment is critical, a new study finds.

Severe combined immunodeficiency (SCID), as the condition is medically known, actually refers to a group of rare genetic disorders that all but eliminate the immune system. That leaves children at high risk of severe infections.

High chance of survival

The term "bubble boy" became popular after a Texas boy with SCID lived in a plastic bubble to ward off infections. The boy, David Vetter, died in 1984 at the age of 12, after an unsuccessful bone marrow transplant -- an attempt to give him a functioning immune system.

Read: 10 immune system boosters

Today, children with SCID have a high chance of survival if they receive an early stem cell transplant, researchers report in the July 31 issue of the New England Journal of Medicine.

In the best-case scenario, a child would get stem cells -- the blood-forming cells within bone marrow - from a sibling who is a perfect match for certain immune-system genes.

But that's not always an option, partly because kids with SCID are often their parents' first child, said Dr. John Cunningham, director of hematopoietic stem cell transplantation at the University of Chicago Comer Children's Hospital. He was not involved in the study.

In those cases, doctors typically turn to a parent -- who is usually a "half" match, but whose stem cells can be purified to improve the odds of success. Sometimes, stem cells from an unrelated, genetically matched donor can be used.

Early detection vital

The good news: Regardless of the donor, children with SCID can frequently be cured, according to the new findings. But early detection and treatment is vital.

Read: Poor sleep affects immune system

"These findings show that if you do these transplants early -- before [the age of] 3.5 months, in a child without infection -- the results are really quite comparable to what you have with a matched sibling," said lead researcher Dr. Richard O'Reilly, chief of the pediatric bone marrow transplant service at Memorial Sloan-Kettering Cancer Center in New York City.

O'Reilly and his colleagues reviewed the cases of 240 infants treated for SCID at 25 U.S. centers between 2000 and 2009. They found that the babies had the best chance of survival if they received a transplant within the first few months of life.

When that happened, 94 percent of children were alive five years later. And survival rates were high -- 77 percent to 93 percent in children without active infections -- even if the donor was not a matched sibling.

If that early time window was missed, infants still had good survival odds if their transplant was done before they developed any infections: Overall, 90 percent were alive five years later, the investigators found.

Read: Gene therapy for 'bubble boy' kids

In contrast, the poorest survival was seen among babies who were older than 3.5 months and had an active infection at the time of their transplant, the study authors noted. Of those 91 children, half died.

"Early diagnosis really makes for the best outcomes," O'Reilly said. "If we focus on that, we might get close to eradicating this."

Screening test

Early diagnosis is becoming more common because there is now a newborn screening test. In 2010, U.S. health officials recommended that states include SCID in their newborn screening panels. So far, 21 states and the District of Columbia have done so, according to the Immune Deficiency Foundation, a nonprofit that is tracking the trend.

SCID is rare: In the United States, an estimated 40 to 100 babies are born with the condition each year, according to the U.S. National Institutes of Health.

O'Reilly noted that some have questioned whether newborn screening is "worth it."

Read: Immune system disorders

"I'd say that it is," he said.

Cunningham agreed. "Every state should institute newborn screening, because the outcomes are so good with early transplants," he said.

Once a child has survived five years, it's essentially considered a "cure," Cunningham noted. In the long run, those kids do well, he said -- though some need to keep taking immunoglobulin, either through a monthly IV treatment or more frequent self-injections, to prevent infections.

Researchers are also studying gene therapy for SCID, with some promising results so far.

"Stem cell transplant is the gold standard," Cunningham noted. "Gene therapy would have to come up to that standard."

But even though early transplants are often successful, Cunningham said he thinks there is a place for gene therapy - and, in general, room for improvement in SCID treatment.

"We don't want to stop at 90 percent survival," he said. "We want to cure 100 percent."

Read more
Boosting foetal immunity
Immune system regulates skin organisms
Bone marrow transplant recipients prone to suicide


We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
Eskom has considered continuous load shedding at Stage 2, instead of introducing it when the power system faces a crunch. What are your thoughts?
Please select an option Oops! Something went wrong, please try again later.
Results
I'm all for it - we're going to have power cuts regardless, so we might as well have some stability to better plan our lives
45% - 4190 votes
No thanks! I prefer having periods of no load shedding and we cannot normalise this crisis
55% - 5065 votes
Vote
Rand - Dollar
17.93
-1.8%
Rand - Pound
19.45
-0.0%
Rand - Euro
17.37
-0.0%
Rand - Aus dollar
11.70
-0.0%
Rand - Yen
0.13
-0.0%
Gold
1,643.66
0.0%
Silver
18.87
0.0%
Palladium
2,073.00
0.0%
Platinum
858.50
0.0%
Brent Crude
86.15
-5.0%
Top 40
57,110
-3.1%
All Share
63,417
-2.9%
Resource 10
56,319
-7.5%
Industrial 25
78,436
-1.2%
Financial 15
14,142
-1.6%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE